Literature DB >> 35144666

miR-27a inhibits molecular adhesion between monocytes and human umbilical vein endothelial cells; systemic approach.

Farhad Shaikhnia1, Ghasem Ghasempour1, Asghar Mohammadi2, Mohammad Shabani3, Mohammad Najafi4,5,6.   

Abstract

OBJECTIVE: The endothelial cells overexpress the adhesion molecules in the leukocyte diapedesis pathway, developing vessel subendothelial molecular events. In this study, miR-194 and miR-27a were predicted and investigated on the expression of adhesion molecules in HUVEC cells. The SELE, SELP, and JAM-B adhesion molecules involved in the leukocyte tethering were predicted on the GO-enriched gene network. Following transfection of PEI-miRNA particles into HUVEC cells, the SELE, SELP, and JAM-B gene expression levels were evaluated by real-time qPCR. Furthermore, the monocyte-endothelial adhesion was performed using adhesion assay kit.
RESULTS: In agreement with the prediction results, the cellular data showed that miR-27a and miR-194 decrease significantly the SELP and JAM-B expression levels in HUVECs (P < 0.05). Moreover, both the miRNAs suppressed the monocyte adhesion to endothelial cells. Since the miR-27a inhibited significantly the monocyte-endothelial adhesion (P = 0.0001) through the suppression of SELP and JAM-B thus it might relate to the leukocyte diapedesis pathway.
© 2022. The Author(s).

Entities:  

Keywords:  Adhesion; HUVEC cells; JAM-B (2); SELE; SELP; miR-194; miR-27a

Mesh:

Substances:

Year:  2022        PMID: 35144666      PMCID: PMC8830077          DOI: 10.1186/s13104-022-05920-9

Source DB:  PubMed          Journal:  BMC Res Notes        ISSN: 1756-0500


Introduction

Atherosclerosis is the leading cause of coronary artery diseases (CAD), peripheral artery diseases (PAD), and cerebrovascular diseases (CVD) including myocardial infarction, stroke, and heart failure [1, 2]. Many studies showed that inflammatory events such as hypercholesterolemia, dyslipidemia, and hypertension are known as important risk factors of atherosclerosis [3, 4]. Moreover, the process of atherosclerosis progresses due to endothelial cell activation, monocyte recruitment, and macrophage polarization in the vessel sub-endothelial space [5, 6]. LDL-cholesterol, cytokines and cell damages play the key roles at the beginning of atherosclerosis [5]. The LDL particles accumulate in the intima of arteries and convert to oxidized-LDL (Ox-LDL) mainly due to Reactive Oxygen/Nitrogen Species (ROS/RNS) produced in various cells such as vascular smooth muscle cells (VSMCs), endothelial cells, and macrophages [4]. Ox-LDL and other inflammatory cytokines are able to activate endothelial cells and to induce the expression of adhesion molecules such as ICAM-1, VCAM-1, E-selectin (SELE), and P-selectin (SELP) on the cellular surfaces [7-10]. Inclacumab, a human monoclonal antibody against P-selectin inhibits the leukocyte rolling [11]. Furthermore, the monocyte diapedesis is a process mediated by junctional adhesion molecules (JAMs) [12-16]. JAMs belong to an immunoglobulin superfamily (JAM-A, B, and C) and express on both leukocyte and endothelial cells [17-19]. Following the monocyte diapedesis, some factors such as monocyte chemotactic protein-1 (MCP-1), macrophage colony-stimulating factor (M-CSF), and IL-8 affect macrophage polarization [4]. Macrophages scavenge the ox-LDL and convert to foam cells resulting in more recruitment of monocytes, lymphocytes, and SMCs into atheroma plaque [4]. Finally, macrophages by production of matrix metalloproteinase enzymes (MMPs) degrade the extracellular matrix (ECM), causing plaque remodeling [1–3, 5, 6]. In the other hand, microRNAs (miRNA/miR) are small nucleotides that affect the cellular pathways via the regulation of gene expression levels [13, 20, 21]. Many studies reported that microRNAs might retard atherosclerosis process by targeting some genes such as adhesion molecules [20, 22]. In this study, miR-194 and miR-27a were predicted using miRNA-gene databases and monocyte-endothelial adhesion was evaluated through the changes of P-selectin, E-selectin, and JAM-B gene expression levels.

Main text

Methods

Cell culture

Human umbilical vein endothelial cells (HUVEC; C554) were purchased from Pasteur Institute (Tehran) and were seeded and cultured in DMEM-F12 (containing FBS 10% (Gibco, Thermo Fisher Scientific-US) and Pen-strep 1% (Sigma-Aldrich Co., St Louis, MO, USA)) in normal conditions (5% CO2, 37 °C).

microRNA transfection

To deliver microRNAs into HUVEC cells, Polyethylenimine (PEI, Sigma Aldrich) was used. N/P ratio equal to 20 from each PEI-miR complex (containing miR-194, miR-27a, and scramble) was made and added to the culture medium of HUVEC cells for 4 h. Then, the cells were washed by PBS and were maintained for 24 h.

Flow cytometry

To evaluate miRNA transfection, the flow cytometry technique was used. After incubating the cells with PEI containing FITC-conjugated miRNA for 4 h, they were harvested and examined by flow cytometry technique (CyFlow, Partec, Germany).

RNA extraction, cDNA synthesis, and RT-qPCR

Total RNA was extracted by GeneAll-Hybrid-R RNA purification kit (Seoul, South Korea). cDNA was synthesized using Reverse Transcriptase HyperScript™ First-strand Synthesis Kit (Seoul, South Korea). Real Time-qPCR was accomplished by TB Green Premix Ex Taq (Tli RNase H Plus) (Takara, Seoul, South Korea) using StepOne instrument (Applied Biosystems, Foster City, CA, USA). The gene expression data were normalized with beta-actin (ACTB), a house-keeping gene, to access relative gene expression. The primers of SELE (F-AGAATCAGAAACAGGTGC and R-GATGGGTGTTGCGGTTTCAG), SELP (F-ACGCTGCATTTGACCCGAG and R- CCCAAACTCAGGAAACAGGGT), JAM-B (F-GACAAGAAGTGATGCGGGGA and R- ATGATGGAACTGCTGGAGCC), and ACTIN-B (F-GCAAGCAGGAGTATGACGA and R- CAAACAAATAAAGCCATGCCAATC) were designed and checked by primer blast server.

Monocyte-endothelial adhesion

Monocytes from healthy subjects were isolated from whole blood by RosetteSep™ Human Monocyte Enrichment Cocktail kit (STEMCELL Technologies Canada Inc.). After incubating (24 h), the miRNA-transfected HUVEC cells were cocultured with isolated monocytes. Then, the molecular adhesion was assessed by CytoSelect™ Leukocyte-endothelium Adhesion Assay kit (Cell Bio labs, Inc. San Diego, CA 92126 USA).

Gene and miRNA predictions

The membrane genes were extracted from REACTOME and were improved on the STRING server (Fig. 1A). The gene data were merged with the diapedesis pathway (KEGG, hsa04670) and were presented as clusters with high-edge nodes using Cytoscape (Fig. 1B). Then, the cluster genes were enriched using GO (molecular function, molecular process) so that three genes (JAM2, SELP, and SELE) were found to be involved with leucocyte tethering on rolling function and process (Fig. 1C). In the other hand, the genes were subjects to search in miRNA databases through miRWalk server. The primary gene-miRNA networks were evaluated and trimmed on the high-frequency reports of the databases so that several miRNAs were predicted to relate to the function of genes. The high-edge miRNAs containing miR-194-5p and miR-27a-3p were selected for the study (Fig. 1D) [23, 24].
Fig. 1

Gene and RNA predictions. A Gene network obtained from REACTOME membrane data. B The high-score common genes in diapedesis pathway. C GO enrichment. D Gene-miRNA network

Gene and RNA predictions. A Gene network obtained from REACTOME membrane data. B The high-score common genes in diapedesis pathway. C GO enrichment. D Gene-miRNA network

Statistical analysis

Data were analyzed using Graphpad Prism (Version 8.0.3, San Diego, CA). The significant changes in the study groups were detected by ANOVA followed with Dunn’s post hoc test. P-values < 0.05 were considered as significant levels. 2−ΔΔCt method was used to investigate the gene expression values.

Results

The cellular uptake of FITC-labeled PEI/miR complex showed that the miRNA delivery was above 98% in human umbilical vein endothelial cells (Fig. 2).
Fig. 2

miRNA transfection in human umbilical vein endothelial cells. The PEI particles containing FITC-conjugated miRNA were transfected into cells and the delivery levels were estimated up to 98% using flow cytometry. Scattered light plot of SSC (side scatter) vs FSC (forward scatter). FL1 (fluorescence channel 1) vs. FL2 (orange channel 2) scatter and count plots

miRNA transfection in human umbilical vein endothelial cells. The PEI particles containing FITC-conjugated miRNA were transfected into cells and the delivery levels were estimated up to 98% using flow cytometry. Scattered light plot of SSC (side scatter) vs FSC (forward scatter). FL1 (fluorescence channel 1) vs. FL2 (orange channel 2) scatter and count plots

Gene expression

miR-194 and miR-27a decreased SELP gene expression level

The changes in SELP gene expression levels were significant in the cells treated with miR-194 (P = 0.037). Also, miR-27a decreased significantly the SELP gene expression levels (P = 0.0250) (Fig. 3-A).
Fig. 3

The gene expression levels and monocyte adhesion in HUVECs. The gene expression levels of SELP (A), SELE (B) and JAM-B (C). D Monocyte-endothelial adhesion. The molecular adhesion was evaluated in the miRNA-transfected HUVEC cells cocultured with monocytes. Relative Fluorescence Unit (RFU %) as the index of cellular adhesion level. *P-value < 0.05, **P-value < 0.0001, ***P-value = 0.0005

The gene expression levels and monocyte adhesion in HUVECs. The gene expression levels of SELP (A), SELE (B) and JAM-B (C). D Monocyte-endothelial adhesion. The molecular adhesion was evaluated in the miRNA-transfected HUVEC cells cocultured with monocytes. Relative Fluorescence Unit (RFU %) as the index of cellular adhesion level. *P-value < 0.05, **P-value < 0.0001, ***P-value = 0.0005

miR-194 and miR-27a did not change SELE gene expression level

The miR-194 and miR-27a had no significant effects on the SELE gene expression levels (P = 0.9920 and P = 0.9945, respectively) (Fig. 3B).

miR-194 and miR-27a decreased JAM-B gene expression level

miR-194 and miR-27a decreased significantly the JAM-B gene expression levels in HUVEC cells (P = 0.0005 and P < 0.0001, respectively) (Fig. 3C).

miR-27a inhibited significantly monocyte-endothelial Adhesion

Data on monocyte-endothelial adhesion revealed that miR-27a inhibits significantly (P < 0.0001) monocyte adhesion to endothelial cells. miR-194, however, reduced the monocyte-endothelial adhesion but there was not significant difference as considered to miR-27a (P = 0.5243) (Fig. 3-D).

Discussion

The activated endothelial cells might overexpress adhesion molecules and enhance leukocyte adhesion following rolling, strong adhesion, crawling, and transmigration processes [7]. Many studies showed that non-coding RNAs target the adhesion molecules and other genes involved in vessel stenosis [20-24]. This study was focused on the effects of miRNA-related genes predicted in the monocyte diapedesis process. Some studies reported that circulating miR-27a decreases in patients with atherosclerosis and suggested to be a biomarker in diagnosis and follow-up of these patients [25]. Moreover, it is suggested that miR-27a shifts the monocyte polarization to macrophage M2 and affects plaque formation [22]. Sun Y et al. showed miR-27a suppresses FADD and prevents from HUVEC apoptosis [26]. Wang Y et al. reported miR-27a inhibits inflammation and cell adhesion in rat kidney epithelial cells by targeting TLR-4 [27]. Romay MC et al. reported miR-27a and miR-21 modulate NF-κB signaling pathway and inhibit the expression of adhesion molecules such as SELE and VCAM-1 in HAEC cells [28]. Wu XY et al. showed that miR-155 targets directly P-65 in NF-κB signaling pathway and inhibits the adhesion of monocytes to HUVECs [29]. miR-27a and b also regulate endothelial adhesion and angiogenesis by suppression of NF‐κB and SEMA6A [30-32]. In agreement with above reports, this study showed that the miR-27a decreases the SELP and JAM-B gene expression levels. This study also showed that miR-27a suppresses significantly the monocyte-endothelial adhesion. However, miR-27a cannot change the E-selectin expression level. It is well known that SELP and JAM-B express by endothelial cells in inflammatory events and bind to monocytes during diapedesis process [16, 18, 19, 33]. Moreover, the results showed that the miR-194 downregulates the JAM-B and SELP gene expression levels in endothelial cells. In agreement with these results, other studies on miR-194 reported that it suppresses the TGF-β/SMAD signaling pathway by targeting THBS1 resulting in the inhibition of inflammation and vasopermeability [34]. Chen R et al. showed that miR-194 inhibits CXCR4 and decreases the expression of IL-1β, IL-6, and TNF-α [35]. In this study, the monocyte-endothelial adhesion was inhibited by miR-194 but not significantly. This phenotype finding might be because more suppression of JAM-B and SELP genes by miR-27a as compared with the miR-194. Taken together, the prediction results showed that the SELP, JAM-B, and SELE genes might effectively affect the leukocyte diapedesis process by miR-27a and miR-194. The experimental results confirmed the effects of miR-27a and miR-194 on the suppression of the SELP and JAM-B gene expression levels. However, there were no correlations between SELE and miRNAs due to the predicted low-score edges as compared with other edges. Furthermore, the data found a relation between miR-27a and the JAM-B expression levels that were not considered in prediction results.

Conclusion

The results showed that the miR-27a inhibits effectively the monocyte-endothelial adhesion by suppressing the adhesion molecules in HUVEC cells.

Limitation

The work is validated on the prediction studies. The results can improve by the focus on the molecular mechanisms between the studied miRNAs and genes and to experience their roles in interventional experiments.
  34 in total

1.  Dual interaction of JAM-C with JAM-B and alpha(M)beta2 integrin: function in junctional complexes and leukocyte adhesion.

Authors:  Chrystelle Lamagna; Paolo Meda; Guillaume Mandicourt; James Brown; Robert J C Gilbert; E Yvonne Jones; Friedemann Kiefer; Pilar Ruga; Beat A Imhof; Michel Aurrand-Lions
Journal:  Mol Biol Cell       Date:  2005-08-10       Impact factor: 4.138

Review 2.  Monocyte trafficking across the vessel wall.

Authors:  Teresa Gerhardt; Klaus Ley
Journal:  Cardiovasc Res       Date:  2015-05-19       Impact factor: 10.787

3.  MicroRNA-27a/b controls endothelial cell repulsion and angiogenesis by targeting semaphorin 6A.

Authors:  Carmen Urbich; David Kaluza; Timo Frömel; Andrea Knau; Katrin Bennewitz; Reinier A Boon; Angelika Bonauer; Carmen Doebele; Jes-Niels Boeckel; Eduard Hergenreider; Andreas M Zeiher; Jens Kroll; Ingrid Fleming; Stefanie Dimmeler
Journal:  Blood       Date:  2011-12-19       Impact factor: 22.113

4.  Regulation of microRNA-155 in endothelial inflammation by targeting nuclear factor (NF)-κB P65.

Authors:  Xiao-Yuan Wu; Wen-Dong Fan; Rong Fang; Gui-Fu Wu
Journal:  J Cell Biochem       Date:  2014-11       Impact factor: 4.429

Review 5.  MicroRNA Regulation of Atherosclerosis.

Authors:  Mark W Feinberg; Kathryn J Moore
Journal:  Circ Res       Date:  2016-02-19       Impact factor: 17.367

Review 6.  Inflammation in atherosclerosis: from pathophysiology to practice.

Authors:  Peter Libby; Paul M Ridker; Göran K Hansson
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

Review 7.  The role of junctional adhesion molecules in vascular inflammation.

Authors:  Christian Weber; Line Fraemohs; Elisabetta Dejana
Journal:  Nat Rev Immunol       Date:  2007-06       Impact factor: 53.106

Review 8.  MicroRNAs and atherosclerosis.

Authors:  Julio Madrigal-Matute; Noemi Rotllan; Juan F Aranda; Carlos Fernández-Hernando
Journal:  Curr Atheroscler Rep       Date:  2013-05       Impact factor: 5.113

9.  miR‑27a suppresses TLR4‑induced renal ischemia‑reperfusion injury.

Authors:  Yang Wang; Dan Wang; Zhen Jin
Journal:  Mol Med Rep       Date:  2019-06-04       Impact factor: 2.952

Review 10.  Immunity, atherosclerosis and cardiovascular disease.

Authors:  Johan Frostegård
Journal:  BMC Med       Date:  2013-05-01       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.